Le Lézard
Classified in: Health
Subject: SVY

Pharmaceutical Continuous Manufacturing Market to Attain a Value of US$3.693 Billion in 2025 Globally: Transparency Market Research



ALBANY, New York, October 5, 2017 /PRNewswire/ --

Many pharmaceutical manufacturers are switching to continuous production from batch methods. In continuous production, active ingredients are produced in compact, closed units, leveraging automation and fewer manual interventions. Production steps carried out sequentially in a classic batch process are integrated in a continuous process. The main unique perceived benefit of pharmaceutical continuous manufacturing technology is that it brings about continued utilization of production capacity. This in turn serves to reduce fluctuations in production, improve yields, and lower costs of operation and equipment. On account of such advantages, the method is seeing swift uptake.

View Full Report at https://www.transparencymarketresearch.com/pharmaceutical-continuous-manufacturing-technology-market.html

As per a report by Transparency Market Research, the global pharmaceutical continuous manufacturing technology market will likely rise at a healthy CAGR of 8.8% during the period between 2017 and 2025. Expanding at this pace, the market which was worth US$1.74 bn in 2016 is expected to attain a value of US$3.693 bn in 2025.

Safety of Process Makes it Popular 

Apart from the aforementioned benefits, other advantages of pharmaceutical continuous manufacturing technology is the superior development speeds, higher process safety when employing hazardous chemistries, and the opportunity to perform reactions that cannot be run under batch processing. "Monitoring and control are at the center of successful continuous manufacturing process which is not possible without process analytical technology (PAT); immediate and ongoing feedback of critical process parameters is vibrant if optimum processing conditions is maintained.

Request to View Sample Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=20840

Progress in PAT have been substantial in the recent past, and today there is a wide array of tools applicable for the real-time monitoring of manufacturing processes for both drug substances and drug products. Ultimately continuous process is primed to succeed owing to the maturing of a mix of sophisticated technologies leading to better equipment, accurate monitoring, automation, and software," explains the lead analyst of the TMR report.

Some of the key application segments of the global pharmaceutical continuous manufacturing technology market are biologics, dry powders, active pharmaceutical ingredients, etc. Of them, the segment of biologics accounts for a dominant position in the market. It held a share of about 35.3% in the global market in 2016. It was trailed by active pharmaceutical ingredient.

Request to download and view full ToC - https://www.transparencymarketresearch.com/report-toc/20840

The key geographic regions in the global pharmaceutical continuous manufacturing technology market studied in the report are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Among them, Europe leads the market with maximum share on the back of rising demand for superior technology from contract manufacturing organizations and pharmaceutical companies. The region accounted for a leading 35% share in the market in 2016. In the years ahead too, the region is expected to retain its leading position in the market by expanding at maximum pace. This is mainly on account of the early availability of advanced technologies and greater number of technology providers across the region.

Some of the prominent participants in the global pharmaceutical continuous manufacturing technology market are Siemens AG, GEA group, Continuus Pharmaceutical, S K Biotek ltd, Korsch AG, Scott Equipment Company, Corning Life Sciences, and Chemtrix.

Global Pharmaceutical Continuous Manufacturing Market Report is available @ US$ 5795

About TMR 

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.


Contact
Transparency Market Research
State Tower
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com
TMR Blog: http://www.theglobalhealthnews.com/



These press releases may also interest you

at 21:37
BD (Becton, Dickinson and Company) announced today that, in connection with its previously announced offers to exchange (the "Exchange Offers") any and all outstanding 4.400% Notes due 2021, 3.000% Notes due 2026 and 6.700% Notes due 2026...

at 19:33
Resverlogix Corp. ("Resverlogix" or the "Company") announced today that it has filed its unaudited interim Consolidated Financial Statements and Management's Discussion & Analysis for the quarter ended October 31, 2017 with Canadian securities...

at 19:06
Health Canada is advising Canadians that the following products may pose serious health risks. For more information, including what Canadians should do, visit the online safety alert.   Unauthorized health products Product & Promoted Use...

at 19:03
ICC Labs Inc. ("ICC Labs" or the "Company") , a fully licensed producer and distributor of medicinal cannabinoid extracts, recreational cannabis and industrial hemp products in Uruguay, is pleased to announce it has changed its name from ICC...

at 18:37
Update This notice is being updated to include additional provinces, Ontario and Nova Scotia, which have reported illnesses linked to this outbreak. Since the original notice was issued, there are nine additional cases of E. coli that have been...

at 18:25
MiMedx Group, Inc. , the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today...




News published on 5 october 2017 at 09:30 and distributed by: